Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Cysteine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cysteine SCHEMBL28238218 | 1.00 | PTGS1 (0.94) | — | |
| Cysteine SCHEMBL730594 | 1.00 | — | — | |
| Cysteine SCHEMBL1573764 | 1.00 | PTGS1 (0.94) | — | |
| Cysteine SCHEMBL18160 | 1.00 | — | — | |
| Cysteine SCHEMBL1573765 | 1.00 | PTGS1 (0.94) | — | |
| Cysteine SCHEMBL50242 | 1.00 | — | — | |
| Cysteine SCHEMBL17394843 | 1.00 | PTGS1 (0.94) | — | |
| Cysteine SCHEMBL16894009 | 1.00 | PTGS1 (0.94) | — | |
| Cysteine SCHEMBL16894007 | 1.00 | PTGS1 (0.94) | — | |
| Cysteine SCHEMBL7610984 | 1.00 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 133 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114892444-B | Paper-based mulching film and preparation method and application thereof | 南京林业大学 | 2023-05-09 | — | — | CN | claimed |
| CN-114892444-A | Paper-based mulching film and preparation method and application thereof | 南京林业大学 | 2022-08-12 | — | — | CN | claimed |
| CN-110468102-A | A kind of method of in vitro culture tuberculosis infection T cell | GUANGZHOU FENGHUA BIOENGINEERING CO LTD | 2019-11-19 | — | — | CN | claimed |
| CN-110269934-A | A kind of preparation method of the biological agent of WT1 gene anticancrin | 海南诺倍尔生态医学科学研究院有限公司 | 2019-09-24 | — | — | CN | claimed |
| CN-110241170-A | A kind of pure chemistry synthetic proteins peptone water reference culture medium and its preparation method and application | 山西省食品药品检验所(山西省药品包装材料监测中心) | 2019-09-17 | — | — | CN | claimed |
| CN-110066763-A | Promote the method for ox embryo in vitro culture development of fertilized ova | 天津博裕力牧科技有限公司 | 2019-07-30 | — | — | CN | claimed |
| CN-110066764-A | Promote the method for ox embryo in vitro culture oocyte in vitro maturation | 天津博裕力牧科技有限公司 | 2019-07-30 | — | — | CN | claimed |
| CN-109943522-A | A kind of mammalian in vitro fertilization Embryo Culture method | 南京鼓楼医院 | 2019-06-28 | — | — | CN | claimed |
| CN-109420168-A | A kind of biological agent technology of preparing inhibiting WT1 gene mutation | 海南诺倍尔生态医学科学研究院有限公司 | 2019-03-05 | — | — | CN | claimed |
| CN-109363965-A | Fibrous bud mother cell activating solution and facial mask | 山东斯滕生物科技有限公司 | 2019-02-22 | — | — | CN | claimed |
| CN-109321451-A | It is a kind of can multiple groups experiment zebrafish embryo acute toxicity detection kit | 常州市环境监测中心 | 2019-02-12 | — | — | CN | claimed |
| CN-109321525-A | The non-animal derived culture medium of NK cell | 山东斯滕生物科技有限公司 | 2019-02-12 | — | — | CN | claimed |
| CN-109022356-A | A kind of serum free medium improving mesenchymal stem cells into chondrocytes differentiation | 丰泽康生物医药（深圳）有限公司 | 2018-12-18 | — | — | CN | claimed |
| CN-108865995-A | Promote Fiber differentiation composition and its application of the CD8 positive T cell proliferation in spleen source | 深圳市拓普生物科技有限公司 | 2018-11-23 | — | — | CN | claimed |
| CN-108795689-A | A kind of preparation method of Candida biofilm flow model | 安徽中医药大学 | 2018-11-13 | — | — | CN | claimed |
| CN-108753689-A | The method of ox IVF Embryos culture | 天津博裕力牧科技有限公司 | 2018-11-06 | — | — | CN | claimed |
| CN-108728404-A | Ox live body or the method for in vitro oocyte collection IVF Embryos culture | 天津博裕力牧科技有限公司 | 2018-11-02 | — | — | CN | claimed |
| CN-108728401-A | The method of IVF of Oocyte in Bovine Embryo Culture and culture medium used | 天津博裕力牧科技有限公司 | 2018-11-02 | — | — | CN | claimed |
| US-9943545-B2 | Stem cell culture media and methods of enhancing cell survival | FATE THERAPEUTICS, INC. (US) | 2018-04-17 | — | — | US | claimed |
| US-12364747-B2 | Stabilized live attenuated influenza vaccine compositions | SERUM INSTITUTE OF INDIA PRIVATE LIMITED (IN) | 2025-07-22 | — | — | US | disclosed |
| US-20240425894-A1 | CELL CULTURE PROCESSES | UCB Biopharma SRL (BE) | 2024-12-26 | — | — | US | disclosed |
| CN-115927171-B | Culture medium for rapid differentiation of freshwater fish muscle stem cells and application thereof | 中国海洋大学 | 2024-08-06 | — | — | CN | disclosed |
| CN-118184697-A | Amino acid derivative with phosphonate structure and application thereof in preparation of anti-hypoxia drugs | 中国人民解放军联勤保障部队第九〇四医院 | 2024-06-14 | — | — | CN | disclosed |
| CN-117881437-A | Collagen IV biological ink | 悉尼大学 | 2024-04-12 | — | — | CN | disclosed |
| CN-117836021-A | Bioengineered endothelial structures | 悉尼大学 | 2024-04-05 | — | — | CN | disclosed |
| CN-117599029-A | Compositions for controlled release of cysteamine and systematic treatment of cysteamine-sensitive disorders | 硫创治疗公司 | 2024-02-27 | — | — | CN | disclosed |
| EP-4323537-A1 | CELL CULTURE PROCESSES | UCB Biopharma SRL (BE) | 2024-02-21 | — | — | EP | disclosed |
| CN-117242186-A | Cell culture method | UCB生物制药有限责任公司 | 2023-12-15 | — | — | CN | disclosed |
| US-20230355649-A1 | FORMULATIONS OF ANTI-VIRAL COMPOUNDS | SAYVAA PHARMACEUTICALS INC. | 2023-11-09 | — | — | US | disclosed |
| US-11786491-B2 | Compositions for controlled release of cysteamine and systemic treatment of cysteamine sensitive disorders | THIOGENESIS THERAPEUTICS, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| EP-4203937-A1 | FORMULATIONS OF ANTI-VIRAL COMPOUNDS | Sayvaa Pharmaceuticals Inc. (US) | 2023-07-05 | — | — | EP | disclosed |
| CN-116367837-A | Formulations of antiviral compounds | 塞瓦药品公司 | 2023-06-30 | — | — | CN | disclosed |
| CN-114892444-B | Paper-based mulching film and preparation method and application thereof | 南京林业大学 | 2023-05-09 | — | — | CN | disclosed |
| CN-114892444-B | Paper-based mulching film and preparation method and application thereof | 南京林业大学 | 2023-05-09 | — | — | CN | disclosed |
| CN-115927171-A | Culture medium for rapid differentiation of muscle stem cells of freshwater fishes and application of culture medium | 中国海洋大学 | 2023-04-07 | — | — | CN | disclosed |
| WO-2022219059-A1 | CELL CULTURE PROCESSES | UCB Biopharma SRL (BE) | 2022-10-20 | — | — | WO | disclosed |
| CN-114892444-A | Paper-based mulching film and preparation method and application thereof | 南京林业大学 | 2022-08-12 | — | — | CN | disclosed |
| CN-114892444-A | Paper-based mulching film and preparation method and application thereof | 南京林业大学 | 2022-08-12 | — | — | CN | disclosed |
| US-20220211837-A1 | LIVE ATTENUATED INFLUENZA VACCINE COMPOSITION AND PROCESS FOR PREPARATION THEREOF | SERUM INSTITUTE OF INDIA PVT LTD. (IN) | 2022-07-07 | — | — | US | disclosed |
| WO-2022047441-A1 | FORMULATIONS OF ANTI-VIRAL COMPOUNDS | EMPHASCIENCE, INC. (US) | 2022-03-03 | — | — | WO | disclosed |
| US-20220040127-A1 | COMPOSITIONS FOR CONTROLLED RELEASE OF CYSTEAMINE AND SYSTEMIC TREATMENT OF CYSTEAMINE SENSITIVE DISORDERS | THIOGENESIS THERAPEUTICS, INC. | 2022-02-10 | — | — | US | disclosed |
| US-20210355503-A1 | COMPOSITIONS AND METHODS FOR MANUFACTURING GENE THERAPY VECTORS | NIGHTSTARX LIMITED (GB) | 2021-11-18 | — | — | US | disclosed |
| EP-2357250-B1 | Production of TNFR-Ig | PFIZER IRELAND PHARMACEUTICALS (IE) | 2021-10-06 | — | — | EP | disclosed |
| US-11135244-B2 | Stem cell culture media and methods of enhancing cell survival | FATE THERAPEUTICS, INC. (US) | 2021-10-05 | — | — | US | disclosed |
| EP-3853357-A1 | COMPOSITIONS AND METHODS FOR MANUFACTURING GENE THERAPY VECTORS | NightstaRx Limited (GB) | 2021-07-28 | — | — | EP | disclosed |
| US-20210180008-A1 | MEDIA AND FERMENTATION METHODS FOR PRODUCING POLYSACCHARIDES IN BACTERIAL CELL CULTURE | PFIZER INC. (US) | 2021-06-17 | — | — | US | disclosed |
| US-10947494-B2 | Media and fermentation methods for producing polysaccharides in bacterial cell culture | PFIZER INC. (US) | 2021-03-16 | — | — | US | disclosed |
| WO-2020061581-A1 | COMPOSITIONS AND METHODS FOR MANUFACTURING GENE THERAPY VECTORS | NIGHTSTARX LIMITED (GB) | 2020-03-26 | — | — | WO | disclosed |
| CN-110468102-A | A kind of method of in vitro culture tuberculosis infection T cell | GUANGZHOU FENGHUA BIOENGINEERING CO LTD | 2019-11-19 | — | — | CN | disclosed |
| CN-110366550-A | Benzoisothiazole, isothiazolo [3,4-b ] pyridine, quinazoline, phthalazine, pyrido [2,3-d ] pyridazine and pyrido [2,3-d ] pyrimidine derivatives as KRAS G12C inhibitors for the treatment of lung, pancreatic or colorectal cancer | 美国安进公司 | 2019-10-22 | — | — | CN | disclosed |
| CN-107603943-B | Support the small molecule and its method of pluripotent cell growth | 威盛细胞有限公司 | 2019-10-11 | — | — | CN | disclosed |
| CN-110312533-A | Prodrugs of cytotoxic active agents having an enzymatically cleavable group | 拜耳公司 | 2019-10-08 | — | — | CN | disclosed |
| US-20190292513-A1 | MEDIA AND FERMENTATION METHODS FOR PRODUCING POLYSACCHARIDES IN BACTERIAL CELL CULTURE | PFIZER INC. | 2019-09-26 | — | — | US | disclosed |
| CN-110269934-A | A kind of preparation method of the biological agent of WT1 gene anticancrin | 海南诺倍尔生态医学科学研究院有限公司 | 2019-09-24 | — | — | CN | disclosed |
| CN-110241170-A | A kind of pure chemistry synthetic proteins peptone water reference culture medium and its preparation method and application | 山西省食品药品检验所(山西省药品包装材料监测中心) | 2019-09-17 | — | — | CN | disclosed |
| CN-109943522-A | A kind of mammalian in vitro fertilization Embryo Culture method | 南京鼓楼医院 | 2019-06-28 | — | — | CN | disclosed |
| CN-109689859-A | Culture medium for sub-totipotent stem cells | 普乐思尔活性生物科学有限公司 | 2019-04-26 | — | — | CN | disclosed |
| EP-2924113-B1 | USE OF COPPER AND GLUTAMATE IN CELL CULTURE FOR PRODUCTION OF POLYPEPTIDES | WYETH LLC (US) | 2019-04-10 | — | — | EP | disclosed |
| CN-109420168-A | A kind of biological agent technology of preparing inhibiting WT1 gene mutation | 海南诺倍尔生态医学科学研究院有限公司 | 2019-03-05 | — | — | CN | disclosed |
| CN-109363965-A | Fibrous bud mother cell activating solution and facial mask | 山东斯滕生物科技有限公司 | 2019-02-22 | — | — | CN | disclosed |
| CN-109321525-A | The non-animal derived culture medium of NK cell | 山东斯滕生物科技有限公司 | 2019-02-12 | — | — | CN | disclosed |
| WO-2019014201-A1 | EXTENDED RELEASE MOLINDONE COMPOSITIONS | APICORE US LLC (US) | 2019-01-17 | — | — | WO | disclosed |
| CN-109187826-A | A kind of detection method of the outer component of candida albicans biofilm extracellular matrix protein matter | 安徽中医药大学 | 2019-01-11 | — | — | CN | disclosed |
| CN-109097338-A | A kind of hybridoma cell strain of secretion nifursol residual marker monoclonal antibody | 江南大学 | 2018-12-28 | — | — | CN | disclosed |
| CN-109022356-A | A kind of serum free medium improving mesenchymal stem cells into chondrocytes differentiation | 丰泽康生物医药（深圳）有限公司 | 2018-12-18 | — | — | CN | disclosed |
| CN-108998422-A | It is a kind of secrete Diacloden monoclonal antibody hybridoma cell strain and its application | 江南大学 | 2018-12-14 | — | — | CN | disclosed |
| CN-108865995-A | Promote Fiber differentiation composition and its application of the CD8 positive T cell proliferation in spleen source | 深圳市拓普生物科技有限公司 | 2018-11-23 | — | — | CN | disclosed |
| CN-108795689-A | A kind of preparation method of Candida biofilm flow model | 安徽中医药大学 | 2018-11-13 | — | — | CN | disclosed |
| CN-108753689-A | The method of ox IVF Embryos culture | 天津博裕力牧科技有限公司 | 2018-11-06 | — | — | CN | disclosed |
| CN-108728404-A | Ox live body or the method for in vitro oocyte collection IVF Embryos culture | 天津博裕力牧科技有限公司 | 2018-11-02 | — | — | CN | disclosed |
| CN-108728401-A | The method of IVF of Oocyte in Bovine Embryo Culture and culture medium used | 天津博裕力牧科技有限公司 | 2018-11-02 | — | — | CN | disclosed |
| CN-108699529-A | Chemically-defined media for culturing cell populations comprising Cancer Stem Cells (CSCs) | 普乐思尔活性生物科学有限公司 | 2018-10-23 | — | — | CN | disclosed |
| US-20180193381-A1 | STEM CELL CULTURE MEDIA AND METHODS OF ENHANCING CELL SURVIVAL | FATE THERAPEUTICS, INC. | 2018-07-12 | — | — | US | disclosed |
| EP-2495307-B9 | Production of coagulation factor IX with improved glycosylation pattern | WYETH LLC (US) | 2018-05-02 | — | — | EP | disclosed |
| US-9943545-B2 | Stem cell culture media and methods of enhancing cell survival | FATE THERAPEUTICS, INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-20180070583-A1 | LUNG PERFUSION SOLUTION, AND USE THEREOF FOR THE EX-VIVO PRESERVATION OF A MAMMALIAN LUNG | UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN (IE) | 2018-03-15 | — | — | US | disclosed |
| EP-2495307-B1 | Production of coagulation factor IX with improved glycosylation pattern | WYETH LLC (US) | 2018-02-21 | — | — | EP | disclosed |
| CN-107435037-A | A kind of serum free medium for bhk cell | 上海倍谙基生物科技有限公司 | 2017-12-05 | — | — | CN | disclosed |
| EP-1789571-B1 | Production of TNFR-Ig in a large-scale production cell culture | PFIZER IRELAND PHARMACEUTICALS (IE) | 2017-04-26 | — | — | EP | disclosed |
| EP-1610613-B1 | TOPICAL ANTHELMINTIC VETERINARY FORMULATIONS | MERIAL INC (US) | 2016-12-28 | — | — | EP | disclosed |
| EP-1781803-B1 | PRODUCTION OF ANTI-AMYLOID BETA ANTIBODIES | PFIZER IRELAND PHARMACEUTICALS (IE) | 2016-08-24 | — | — | EP | disclosed |
| WO-2016015094-A1 | TOPICAL COMPOSITION | ACRUX DDS PTY LTD (AU) | 2016-02-04 | — | — | WO | disclosed |
| EP-2924113-A1 | USE OF COPPER AND GLUTAMATE IN CELL CULTURE FOR PRODUCTION OF POLYPEPTIDES | Wyeth LLC (US) | 2015-09-30 | — | — | EP | disclosed |
| EP-2366401-B1 | AQUEOUS COMPOSITION CONTAINING FOLLICLE-STIMULATING HORMONE | ASKA PHARM CO LTD (JP) | 2015-07-15 | — | — | EP | disclosed |
| EP-2064315-B1 | GLYCOLYSIS-INHIBITING SUBSTANCES IN CELL CULTURE | WYETH LLC (US) | 2015-05-13 | — | — | EP | disclosed |
| US-9012180-B2 | Use of copper and glutamate in cell culture for production of polypeptides | WYETH LLC (US) | 2015-04-21 | — | — | US | disclosed |
| EP-2115126-B1 | USE OF COPPER AND GLUTAMATE IN CELL CULTURE FOR PRODUCTION OF POLYPEPTIDES | WYETH LLC (US) | 2015-04-08 | — | — | EP | disclosed |
| US-20150044176-A1 | STEM CELL CULTURE MEDIA AND METHODS OF ENHANCING CELL SURVIVIAL | FATE THERAPEUTICS, INC. (US) | 2015-02-12 | — | — | US | disclosed |
| WO-2012118562-A1 | COMPOSITIONS AND METHODS FOR TREATING DEPRESSION, ADHD AND OTHER CENTRAL NERVOUS SYSTEM DISORDERS EMPLOYING NOVEL BUPROPION COMPOUNDS, AND METHODS FOR PRODUCTION AND USE OF NOVEL BUPROPION COMPOUNDS AND FORMULATIONS | RHINE PHARMACEUTICALS, LLC (US) | 2012-09-07 | — | — | WO | disclosed |
| EP-2495307-A1 | Production of glycoproteins | Wyeth LLC (US) | 2012-09-05 | — | — | EP | disclosed |
| US-8192951-B2 | Glycolysis-inhibiting substances in cell culture | WYETH LLC (US) | 2012-06-05 | — | — | US | disclosed |
| EP-1899454-B1 | SERUM-FREE CULTURE MEDIUM FOR THE PRODUCTION OF RECOMBINANT GONADOTROPINS | ARES TRADING SA (CH) | 2012-05-30 | — | — | EP | disclosed |
| US-8129145-B2 | Fermenting preferential polypeptides using varying temperatures and manganese nutrient broths | WYETH LLC (US) | 2012-03-06 | — | — | US | disclosed |
| US-8093052-B2 | Serum-free culture medium for the production of recombinant gonadotropins | ARES TRADING S.A. (CH) | 2012-01-10 | — | — | US | disclosed |
| EP-2357250-A2 | Production of polypeptides | Wyeth Research Ireland Limited (IE) | 2011-08-17 | — | — | EP | disclosed |
| EP-2348126-A2 | Production of anti-amyloid beta antibodies | Wyeth Research Ireland Limited (IE) | 2011-07-27 | — | — | EP | disclosed |
| EP-1992697-B1 | Production of TNFR-Fc | WYETH RES IRELAND LTD (IE) | 2010-03-17 | — | — | EP | disclosed |
| US-20090306080-A1 | VETERINARY FORMULATION | MERIAL LIMITED | 2009-12-10 | — | — | US | disclosed |
| EP-1781802-B1 | PRODUCTION OF A TNFR-IG FUSION PROTEIN | WYETH RES IRELAND LTD (IE) | 2009-10-21 | — | — | EP | disclosed |
| US-20090124006-A1 | Serum-Free Culture Medium for the Production of Recombinant Gonadotropins | ARES TRADING S.A. (CH) | 2009-05-14 | — | — | US | disclosed |
| US-20090068705-A1 | Use of Copper Glutamate in Cell Culture for Production of Polypeptides | WYETH (US) | 2009-03-12 | — | — | US | disclosed |
| EP-1992697-A1 | Production of TNFR-Fc | Wyeth Research Ireland Limited (IE) | 2008-11-19 | — | — | EP | disclosed |
| EP-1912654-A4 | METHODS FOR SELECTIVELY TREATING COX-2 MEDIATED DISORDERS BY ADMINISTERING GAMMA-TOCOPHEROL | MERIAL LTD (US) | 2008-09-17 | — | — | EP | disclosed |
| US-20080108106-A1 | GLYCOLYSIS-INHIBITING SUBSTANCES IN CELL CULTURE | WYETH (US) | 2008-05-08 | — | — | US | disclosed |
| EP-1912654-A2 | METHODS FOR SELECTIVELY TREATING COX-2 MEDIATED DISORDERS BY ADMINISTERING GAMMA-TOCOPHEROL | Merial Limited (US) | 2008-04-23 | — | — | EP | disclosed |
| US-20080081356-A1 | Production of glycoproteins | WYETH (US) | 2008-04-03 | — | — | US | disclosed |
| WO-2008026044-A2 | PHARMACEUTICAL COMPOSITIONS OF BUPROPION | WOCKHARDT RESEARCH CENTRE (IN) | 2008-03-06 | — | — | WO | disclosed |
| EP-1804810-A4 | METHODS USING GLYCOSAMINOGLYCANS FOR THE TREATMENT OF KIDNEY DISEASE | KERYX BIOPHARMACEUTICALS INC (US) | 2008-02-27 | — | — | EP | disclosed |
| US-7335491-B2 | Production of anti-abeta | WYETH RESEARCH IRELAND LIMITED (IE) | 2008-02-26 | — | — | US | disclosed |
| EP-1804810-A1 | METHODS USING GLYCOSAMINOGLYCANS FOR THE TREATMENT OF KIDNEY DISEASE | Keryx Biopharmaceuticals, Inc. (US) | 2007-07-11 | — | — | EP | disclosed |
| US-20070015822-A1 | Methods for selectively treating COX-2 mediated disorders by administering gamma-tocopherol | MERIAL LIMITED | 2007-01-18 | — | — | US | disclosed |
| WO-2006091571-A2 | METHODS FOR SELECTIVELY TREATING COX-2 MEDIATED DISORDERS BY ADMINISTERING GAMMA-TOCOPHEROL | MERIAL LIMITED (US) | 2006-08-31 | — | — | WO | disclosed |
| WO-2006039709-A1 | METHODS USING GLYCOSAMINOGLYCANS FOR THE TREATMENT OF KIDNEY DISEASE | KERYX BIOPHARMACEUTICALS, INC. (US) | 2006-04-13 | — | — | WO | disclosed |
| US-6991801-B2 | Topical anthelmintic veterinary formulations | MERIAL LIMITED (US) | 2006-01-31 | — | — | US | disclosed |
| EP-1610613-A2 | TOPICAL ANTHELMINTIC VETERINARY FORMULATIONS | Merial Ltd. (US) | 2006-01-04 | — | — | EP | disclosed |
| WO-2005058235-A2 | METHODS USING SULODEXIDE FOR THE TREATMENT OF BLADDER DISEASE | KERYX BIOPHARMACEUTICALS, INC. (US) | 2005-06-30 | — | — | WO | disclosed |
| EP-1429777-A4 | OPHTHALMOLOGIC TREATMENT METHODS USING SELECTIVE INOS INHIBITORS | PHARMACIA CORP (US) | 2005-06-22 | — | — | EP | disclosed |
| WO-2004089239-A2 | TOPICAL ANTHELMINTIC VETERINARY FORMULATIONS | MERIAL LTD. (US) | 2004-10-21 | — | — | WO | disclosed |
| US-20040198676-A1 | Topical anthelmintic veterinary formulations | MERIAL, INC. | 2004-10-07 | — | — | US | disclosed |
| EP-1429752-A1 | NEUROPROTECTIVE TREATMENT METHODS USING SELECTIVE INOS INHIBITORS | Pharmacia Corporation (US) | 2004-06-23 | — | — | EP | disclosed |
| EP-1429777-A1 | OPHTHALMOLOGIC TREATMENT METHODS USING SELECTIVE INOS INHIBITORS | Pharmacia Corporation (US) | 2004-06-23 | — | — | EP | disclosed |
| EP-1392329-A1 | USE OF SULODEXIDE FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE | Keryx Biopharmaceuticals Inc. (US) | 2004-03-03 | — | — | EP | disclosed |
| WO-2003026638-A1 | NEUROPROTECTIVE TREATMENT METHODS USING SELECTIVE INOS INHIBITORS | PHARMACIA CORPORATION (US) | 2003-04-03 | — | — | WO | disclosed |
| WO-2003026668-A1 | OPHTHALMOLOGIC TREATMENT METHODS USING SELECTIVE INOS INHIBITORS | PHARMACIA CORPORATION (US) | 2003-04-03 | — | — | WO | disclosed |
| WO-2003002129-A1 | USE OF SULODEXIDE FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE | KERYX BIOPHARMACEUTICALS INC. (US) | 2003-01-09 | — | — | WO | disclosed |
| EP-1265860-A1 | AMIDINO COMPOUND AND SALTS THEREOF USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS | Pharmacia Corporation (US) | 2002-12-18 | — | — | EP | disclosed |
| US-6306436-B1 | Stabilized, acid-free formulation for sustained release of bupropion hydrochloride | TEVA PHARMACEUTICALS USA, INC. | 2001-10-23 | — | — | US | disclosed |
| WO-2001072703-A1 | AMIDINO COMPOUND AND SALTS THEREOF USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS | PHARMACIA CORPORATION (US) | 2001-10-04 | — | — | WO | disclosed |
| EP-1051167-A1 | PHARMACEUTICAL USES OF OPTICALLY PURE (-) -BUPROPION | SEPRACOR, INC. (US) | 2000-11-15 | — | — | EP | disclosed |
| WO-2000006140-A2 | USE OF MOCLOBEMIDE FOR TREATING CERTAIN PHSYCHIATRIC AND MEDICAL DISORDERS | VELA PHARMACEUTICALS INC. (US) | 2000-02-10 | — | — | WO | disclosed |
| WO-2000006139-A2 | USE OF MOCLOBEMIDE AND METABOLITES FOR TREATING AND PREVENTING SUBSTANCE ABUSE | VELA PHARMACEUTICALS INC. (US) | 2000-02-10 | — | — | WO | disclosed |
| WO-1999038504-A1 | PHARMACEUTICAL USES OF OPTICALLY PURE (-)-BUPROPION | SEPRACOR INC. (US) | 1999-08-05 | — | — | WO | disclosed |
| US-5541231-A | IMPROVING STORAGE STABILITY OF THE ANTIDEPRESSANT, BUPROPION HYDROCHLORIDE | GLAXO WELLCOME INC. (US) | 1996-07-30 | — | — | US | disclosed |
| US-5541231-A | IMPROVING STORAGE STABILITY OF THE ANTIDEPRESSANT, BUPROPION HYDROCHLORIDE | GLAXO WELLCOME INC. (US) | 1996-07-30 | — | — | US | disclosed |